A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : MAOI / monoamine oxidase inhibitor

[Related PubMed/MEDLINE]
Total Number of Papers: 263
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   MAOI  (>> Co-occurring Abbreviation)
Long Form:   monoamine oxidase inhibitor
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
1  2022 Chronic SSRI Treatment, but Not Norepinephrine Reuptake Inhibitor Treatment, Increases Neurogenesis in Juvenile Rats. BrdU, MAOIs, SNRIs, SSRIs, TCAs, TCP
2  2022 Clinically Relevant Drug Interactions with Monoamine Oxidase Inhibitors. MAO, NE
3  2022 Molecular Pathways of the Therapeutic Effects of Ayahuasca, a Botanical Psychedelic and Potential Rapid-Acting Antidepressant. DMT, TAAR1, VMAT
4  2022 Pharmahuasca and DMT Rescue ROS Production and Differentially Expressed Genes Observed after Predator and Psychosocial Stress: Relevance to Human PTSD. DEGs, DLPFC, DMT, HC, PFC, PTSD, ROS
5  2022 Predicting serotonin toxicity in serotonin reuptake inhibitor overdose. CIs, DDD, SNRIs, SSRIs
6  2022 Repurposing monoamine oxidase inhibitors (MAOI) for the treatment of rheumatoid arthritis possibly through modulating reactive oxidative stress mediated inflammatory cytokines. CII, FCA, LPS, RA
7  2022 Syndrome of Inappropriate Antidiuretic Hormone Secretion Following Ayahuasca Use in a Satanic Ritual: A Case Report. GCS, MDMA, SIADH
8  2022 The prescriber's guide to classic MAO inhibitors (phenelzine, tranylcypromine, isocarboxazid) for treatment-resistant depression. ---
9  2021 Ayahuasca for the Treatment of Depression. DMT
10  2021 Impact of chronic medications in the perioperative period -anesthetic implications (Part II). ED, Part II, SNRIs, SSRIs, TCAs
11  2021 Impact of chronic medications in the perioperative period: mechanisms of action and adverse drug effects (Part I). ED, SNRIs, SSRIs, TCAs
12  2021 Monoamine oxidase inhibitors (MAOI): pharmacology, metabolism and application in the treatment of depression MAO
13  2021 [Antidepressive agents and hypertension: A case/no-case study in French pharmacovigilance database]. AD, ROR, SNRI
14  2020 A Brazilian Case of Treatment-Resistant Generalized Anxiety Disorder Successfully Treated with Monoamine Oxidase Inhibitor (MAOI). ---
15  2020 Consequences of a Missed History: A Case of Antidepressant Discontinuation Syndrome. ADDS, SSRI, TCAs, USG
16  2020 Effects of different antidepressant classes on dental implant failure: A retrospective clinical study. AA, CI, OR, SNRI, SSRI, TCA
17  2020 [The next psychoactive drugs: From imipramine to ketamine]. ---
18  2019 Effects of Epacadostat on Brain Extracellular Fluid Concentrations of Serotonin-an Intracerebral Microdialysis Study in Sprague-Dawley Rats. ECF, EPAC, IDO1, SS
19  2019 Relative Effectiveness of Monoamine Oxidase Inhibitor and Tricyclic Antidepressant Combination Therapy for Treatment-Resistant Depression. TCA
20  2019 Relative effectiveness of tricyclic antidepressant versus monoamine oxidase inhibitor monotherapy for treatment-resistant depression. TCA, TRD
21  2019 Serotonin Syndrome: Pathophysiology, Clinical Features, Management, and Potential Future Directions. CNS, NPSs, SS, TPH
22  2019 Syrian rue seeds interacted with acacia tree bark in an herbal stew resulted in N,N-dimethyltryptamine poisoning. DMT
23  2018 Depression increases the risk of inflammatory bowel disease, which may be mitigated by the use of antidepressants in the treatment of depression. CD, SNRI, SSRI, TCA, UC
24  2018 Hybrid caffeic acid derivatives as monoamine oxidases inhibitors: synthesis, radical scavenging activity, molecular docking studies and in silico ADMET analysis. ---
25  2018 Khat: A Substance of Growing Abuse with Adverse Drug Interaction Risks. CNS
26  2018 Vortioxetine Disposition in Obesity: Potential Implications for Patient Safety. BMI, Css
27  2017 Adherence and Persistence Across Antidepressant Therapeutic Classes: A Retrospective Claims Analysis Among Insured US Patients with Major Depressive Disorder (MDD). ADs, MDD, ORs, SNRI, SSRI, TCA
28  2017 Chronic CB1 cannabinoid receptor antagonism persistently increases dendritic spine densities in brain regions important to zebra finch vocal learning and production in an antidepressant-sensitive manner. ---
29  2017 Efficacy of antidepressive medication for depression in Parkinson disease: a network meta-analysis. DA, NMA, PD, SNRI, SSRI, SUCRA, TCA
30  2017 Epidemiology and Economic Burden of Serotonin Syndrome With Concomitant Use of Serotonergic Agents: A Retrospective Study Utilizing Two Large US Claims Databases. SAs, SS, VHA
31  2017 Vasoplegic Shock Treated with Methylene Blue Complicated by Severe Serotonin Syndrome. MB, SS
32  2017 Wearing off: A complex phenomenon often poorly recognized in Parkinson's disease. A study with the WOQ-19 questionnaire. DA, HY, PD, UPDRS
33  2016 "Ping-pong gaze" secondary to monoamine oxidase inhibitor overdose. PPG
34  2016 A rapid and simple method for the determination of psychoactive alkaloids by CE-UV: application to Peganum Harmala seed infusions. ---
35  2016 Augmentation of phenelzine with aripiprazole and quetiapine in a treatment-resistant patient with psychotic unipolar depression: case report and literature review. SGAs
36  2016 Ayahuasca Exposure: Descriptive Analysis of Calls to US Poison Control Centers from 2005 to 2015. AAPCC, DMT, NPDS
37  2016 Development of a mechanism-based pharmacokinetic/pharmacodynamic model to characterize the thermoregulatory effects of serotonergic drugs in mice. 5-MeODMT, PK/PD
38  2016 Modification of 5-methoxy-N,N-dimethyltryptamine-induced hyperactivity by monoamine oxidase A inhibitor harmaline in mice and the underlying serotonergic mechanisms. 5-MeODMT, AUEC, IAA
39  2016 [Antidepressant and tolerance: Determinants and management of major side effects]. SNRI, SSRI, TCA
40  2016 [Combining a classic monoamine oxidase inhibitor with a tricyclic antidepressant in therapy-resistant depression: a case report and literature review]. TCA
41  2014 Effects of combined MAO-B inhibitors and levodopa vs. monotherapy in Parkinson's disease. CDS, DA, PD
42  2014 EMSAM (deprenyl patch): how a promising antidepressant was underutilized. ---
43  2014 New potent antibacterial oxazolidinone (MRX-I) with an improved class safety profile. ---
44  2014 Reducing the Burden of Difficult-to-Treat Major Depressive Disorder: Revisiting Monoamine Oxidase Inhibitor Therapy. ---
45  2014 Soma, food of the immortals according to the Bower Manuscript (Kashmir, 6th century A.D.). ---
46  2014 Synthesis, Biological Evaluation, and Molecular Simulation of Chalcones and Aurones as Selective MAO-B Inhibitors. ---
47  2013 Xanthoangelol and 4-Hydroxyderricin Are the Major Active Principles of the Inhibitory Activities against Monoamine Oxidases on Angelica keiskei K. A. keiskei K, DBH
48  2013 [Phenelzine: legacy or current psychiatric practice?]. ---
49  2012 Developments in harmine pharmacology--implications for ayahuasca use and drug-dependence treatment. DMT, DYRK1A
50  2012 Harmine augments electrically evoked dopamine efflux in the nucleus accumbens shell. DA, MAOA
51  2012 Influence of chronic administration of antidepressant drugs on mRNA for galanin, galanin receptors, and tyrosine hydroxylase in catecholaminergic and serotonergic cell-body regions in rat brain. AD, GAL, LC, NE, SSRI, TH, VTA
52  2012 Levels of biogenic amines in retail market fermented meat products. BA, OPA
53  2012 Prediction of longer-term outcome of treatment-resistant depression in tertiary care. ---
54  2012 Propargylamine-derived multitarget-directed ligands: fighting Alzheimer's disease with monoamine oxidase inhibitors. AD, MTDL
55  2012 The predictive validity of atypical neurovegetative depressive symptoms identified by the first principal component in the DUAG trial of moclobemide versus clomipramine. DUAG, PCA, QSAD
56  2011 MAO-inhibitors in Parkinson's Disease. L-dopa, PD
57  2011 The monoamine oxidase A inhibitor clorgyline is a broad-spectrum inhibitor of fungal ABC and MFS transporter efflux pump activities which reverses the azole resistance of Candida albicans and Candida glabrata clinical isolates. ABC, FLC, HTS, MFS, PCL, R6G
58  2011 [Switch antidepressants: when? How? Why?]. ---
59  2010 Changing epidemiology of intentional antidepressant drug overdose in Victoria, Australia. OD, SSRIs, TCAs, VEMD, VPIC
60  2010 CNS toxicity involving methylene blue: the exemplar for understanding and predicting drug interactions that precipitate serotonin toxicity. ---
61  2010 Phenelzine-induced myocardial injury: a case report. ---
62  2010 Quantification of antidepressants using gas chromatography-mass spectrometry. GC/MS, LLE, SNRI, SSRI, TCA
63  2009 A pragmatic approach to biochemical systems theory applied to an alpha-synuclein-based model of Parkinson's disease. BST, PD
64  2009 An algorithm for the pharmacological treatment of depression. AD
65  2009 Atypical depression: retrospective self-reporting of treatment effectiveness. ---
66  2009 Social anxiety disorder: epidemiology, biology and treatment. SAD, SNRI, SSRI
67  2008 Differential effects of imipramine and phenelzine on corticosteroid receptor gene expression in mouse brain: potential relevance to antidepressant response. GR, HPA, MR, TCA
68  2008 Differential regulation of central BDNF protein levels by antidepressant and non-antidepressant drug treatments. ECS, SSRI, TCA
69  2008 Pharmacological causes of hyperprolactinemia. SSRI
70  2007 A history of the concept of atypical depression. ---
71  2007 Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction. MAOA, SSRI, ST
72  2007 Monoamine oxidase inhibition dramatically prolongs the duration of nicotine withdrawal-induced place aversion. ---
73  2007 Neurological complications of psychiatric drugs: clinical features and management. EPS, NMS, SSRI, TCAs
74  2007 Receptor mediation of exaggerated responses to serotonin-enhancing drugs in serotonin transporter (SERT)-deficient mice. 5-HTP, SERT
75  2007 Serotonin syndrome due to an overdose of moclobemide? ---
76  2007 Treating depression with atypical features. SSRIs, TCAs
77  2007 Treating DSM-IV depression with atypical features. TCAs
78  2006 Effect of I-deprenyl and gliclazide on oxidant stress/antioxidant status and dna damage in a diabetic rat model. EL, MDA, OAD, SOD, TAS
79  2006 Placebo-controlled study examining effects of selegiline in children with attention-deficit/hyperactivity disorder. ADHD
80  2006 Quetiapine for insomnia associated with refractory depression exacerbated by phenelzine. ---
81  2006 Reversal of learned helplessness by selective serotonin reuptake inhibitors in rats is not dependent on 5-HT availability. LH, LLR, PCPA, SSRIs
82  2006 Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial. MDD, STS
83  2005 Heteroarylisopropylamines as MAO inhibitors. ---
84  2005 Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. SRIs
85  2005 Nitric oxide synthesis is required for exercise-induced increases in hippocampal BDNF and phosphatidylinositol 3' kinase expression. L-NAME, NO, PI-3K
86  2005 Parkinson's disease. Diagnosis and the initiation of therapy. CBD, MSA, PD, PSP, VP
87  2005 Screening antidepressants in the chick separation-stress paradigm. NRI, SSRI, TCA
88  2004 Chronic treatment with the monoamine oxidase inhibitor phenelzine increases hypothalamic-pituitary-adrenocortical activity in male C57BL/6 mice: relevance to atypical depression. ---
89  2004 Clinical applications of MAO-inhibitors. SSRI's
90  2004 Combining stimulants with monoamine oxidase inhibitors: a review of uses and one possible additional indication. ---
91  2004 Hallucinogens and dissociative agents naturally growing in the United States. NAC, UDV
92  2003 Clorgyline-induced switch from locomotion to mouthing in sensitization to the dopamine D2/D3 agonist quinpirole in rats: role of sigma and imidazoline I2 receptors. MQB
93  2003 Linezolid: new preparation. In severe gram-positive infections. ---
94  2003 Selegiline in the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial. ADHD
95  2003 Transient behavioral sensitization to nicotine becomes long-lasting with monoamine oxidases inhibitors. ---
96  2003 World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders. SSRIs, TCAs, WFSBP
97  2003 [Elderly patients, classical monoamine oxidase inhibitors and intercurrent somatic diseases]. ---
98  2002 5-Hydroxytryptophan (5-HTP) uptake and decarboxylation in the kitten brain. 5-HTP, DA, IR, NA, TP, VLPH
99  2002 Different effects of phenelzine treatment on EEG topography in waking and sleep in depressed patients. REM
100  2002 Effects of the antidepressant/antipanic drug phenelzine and its putative metabolite phenylethylidenehydrazine on extracellular gamma-aminobutyric acid levels in the striatum. GABA, PEH, PLZ